ACAD ACADIA Pharmaceuticals
- 16.820
- -0.250-1.46%
- 16.820
- 0.0000.00%
ACADIA Pharmaceuticals News
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that on April 10, 2024, the Compensation Committee of Acadia's Board of Directors (the "Committee") granted inducement awards consisting of non-qualified stock
Express News | ACADIA Pharmaceuticals Inc : Needham Cuts Target Price to $30 From $32: Needham Cuts Target Price to $30 From $32
Acadia Pharmaceuticals Presents New DAYBUE Clinical Data At The 2024 American Academy Of Neurology Annual Meeting
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that two oral presentations featuring DAYBUE (trofinetide) findings in Rett syndrome will be presented at the American Academy of Neurology (A
Cracking The Code: Understanding Analyst Reviews For ACADIA Pharmaceuticals
26 analysts have expressed a variety of opinions on ACADIA Pharmaceuticals (NASDAQ:ACAD) over the past quarter, offering a diverse set of opinions from bullish to bearish.The following table provides
Express News | Cantor Fitzgerald Reiterates Overweight on ACADIA Pharmaceuticals, Maintains $37 Price Target
ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 26,574 Shares
Taysha Draws Bullish View at Piper Sandler on Lead Asset
Rett Syndrome - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report 2023 To 2033
HARTFORD, Conn., April 9, 2024 /PRNewswire/ -- Thelansis Knowledge Partners, specialized in pharmaceutical and biopharmaceutical business research and consulting Company that provides data driven res
Analysts' Opinions Are Mixed on These Healthcare Stocks: SAGE Therapeutics (SAGE), Apellis Pharmaceuticals (APLS) and ACADIA Pharmaceuticals (ACAD)
Express News | Needham Reiterates Buy on ACADIA Pharmaceuticals, Maintains $32 Price Target
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), BioMarin Pharmaceutical (BMRN) and ACADIA Pharmaceuticals (ACAD)
Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced the appointment of Dr. Elizabeth H. Z. Thompson as Executive Vice President, Head of Research and Development. Dr. Thompson will lead research and development at
Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Monday, A
Acadia Pharmaceuticals Insider Sold Shares Worth $317,081, According to a Recent SEC Filing
Stephen Davis, Director, CEO, on March 27, 2024, sold 17,714 shares in Acadia Pharmaceuticals (ACAD) for $317,081. Following the Form 4 filing with the SEC, Davis has control over a total of 118,842 s
ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 17,714 Shares
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) On The Verge Of Breaking Even
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. ACADIA Pharmaceuticals Inc., a biopharmaceu
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Acadia Pharmaceuticals Inc. (ACAD) Investigation
New York, New York--(Newsfile Corp. - March 27, 2024) - Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Acadia Pharmaceuticals Inc. ("Acadia " or "the C
ACADIA Pharmaceuticals Is Maintained at Overweight by JP Morgan
ACADIA Pharmaceuticals Is Maintained at Overweight by JP Morgan
Express News | JP Morgan Maintains Overweight on ACADIA Pharmaceuticals, Lowers Price Target to $25
10 Health Care Stocks With Whale Alerts In Today's Session
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth.
Analysis
Price Target
No Data
